



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**FOSTEMSAVIR**

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
FOSTEMSAVIR	RUKOBIA	46684		GPI-10 (1210233040)	

**GUIDELINES FOR USE**

- Does the patient have a diagnosis of human immunodeficiency virus type 1 (HIV-1) infection and meet **ALL** of the following criteria?
  - The patient is 18 years of age or older
  - The requested medication will be used in combination with other antiretroviral(s)
  - The patient is heavily treatment experienced and has multidrug-resistant HIV-1 infection
  - The patient is failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #2 per day.**  
If no, do not approve.

**DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **FOSTEMSAVIR (Rukobia)** requires the following rule(s) be met for approval:

- You have human immunodeficiency virus type 1 (HIV-1) infection
- You are 18 years of age or older
- The requested medication will be used in combination with other antiretroviral(s) (class of medication used to treat HIV)
- You are heavily treatment experienced (previously treated) and have multidrug-resistant HIV-1 infection
- You are failing your current antiretroviral regimen due to resistance, intolerance, or safety considerations

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Rukobia.

**REFERENCES**

Rukobia [Prescribing Information]. Research Triangle Park, NC: GlaxoSmithKline; July 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Created: 07/20

Commercial Effective:07/17/20

Client Approval: 07/20

P&T Approval:07/20

Copyright © 2020 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.